These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 31045645)

  • 21. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
    Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
    Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
    Fujino T
    Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies.
    Marshall CH; Gondek LP; Luo J; Antonarakis ES
    Cancer Res; 2022 Nov; 82(22):4107-4113. PubMed ID: 36040522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss.
    Morganti C; Ito K; Yanase C; Verma A; Teruya-Feldstein J; Ito K
    EMBO Rep; 2022 May; 23(5):e54262. PubMed ID: 35229971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of mutations in TP53 mutated AML.
    Welch JS
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity-induced inflammation exacerbates clonal hematopoiesis.
    Pasupuleti SK; Ramdas B; Burns SS; Palam LR; Kanumuri R; Kumar R; Pandhiri TR; Dave UP; Yellapu NK; Zhou X; Zhang C; Sandusky GE; Yu Z; Honigberg MC; Bick AG; Griffin GK; Niroula A; Ebert BL; Paczesny S; Natarajan P; Kapur R
    J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37071471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal hematopoiesis and hematological malignancy.
    Dunn WG; McLoughlin MA; Vassiliou GS
    J Clin Invest; 2024 Oct; 134(19):. PubMed ID: 39352393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
    Kunimoto H; Nakajima H
    Int J Hematol; 2017 Jul; 106(1):34-44. PubMed ID: 28555413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
    Osman A; Patel JL
    Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DDX41 haploinsufficiency causes inefficient hematopoiesis under stress and cooperates with p53 mutations to cause hematologic malignancy.
    Stepanchick E; Wilson A; Sulentic AM; Choi K; Hueneman K; Starczynowski DT; Chlon TM
    Leukemia; 2024 Aug; 38(8):1787-1798. PubMed ID: 38937548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation.
    Ortmann CA; Dorsheimer L; Abou-El-Ardat K; Hoffrichter J; Assmus B; Bonig H; Scholz A; Pfeifer H; Martin H; Schmid T; Brüne B; Scheich S; Steffen B; Riemann J; Hermann S; Dukat A; Bug G; Brandts CH; Wagner S; Serve H; Rieger MA
    Cell Rep; 2019 May; 27(7):2022-2028.e3. PubMed ID: 31091442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal Hematopoiesis of Indeterminate Potential.
    Heuser M; Thol F; Ganser A
    Dtsch Arztebl Int; 2016 May; 113(18):317-22. PubMed ID: 27215596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clonal haematopoiesis: A concise review].
    Danlos FX; Papo M; Micol JB
    Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aging, hematopoiesis, and the myelodysplastic syndromes.
    Chung SS; Park CY
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):73-78. PubMed ID: 29222239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHIP: is clonal hematopoiesis a surrogate for aging and other disease?
    Gondek LP
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):384-389. PubMed ID: 34889429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Importance of clonal hematopoiesis for hematologic neoplasms].
    Götze KS; Lengerke C
    Inn Med (Heidelb); 2022 Nov; 63(11):1107-1114. PubMed ID: 36125513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HSPA9/mortalin inhibition disrupts erythroid maturation through a TP53-dependent mechanism in human CD34+ hematopoietic progenitor cells.
    Butler C; Dunmire M; Choi J; Szalai G; Johnson A; Lei W; Chen X; Liu L; Li W; Walter MJ; Liu T
    Cell Stress Chaperones; 2024 Apr; 29(2):300-311. PubMed ID: 38508444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.